The FDA has imposed a partial clinical hold on Geron's (GERN) Imetelstat treatment in a trial for myelofibrosis, as the drug may be toxic to the liver.
Geron can't enroll new patients into the study, although patients who are benefiting from the treatment will be able to continue receiving it.
The FDA's action adds to the full holds it placed on Phase II trials for essential thrombocythemia and multiple myeloma.
Geron's shares are flat after being higher earlier. (PR)